Chromadex (CDXC) Given a $8.00 Price Target at HC Wainwright
A number of other research firms have also recently commented on CDXC. ValuEngine upgraded shares of Chromadex from a sell rating to a hold rating in a research report on Thursday. BidaskClub cut shares of Chromadex from a strong-buy rating to a buy rating in a research report on Friday, December 22nd. Finally, Zacks Investment Research upgraded shares of Chromadex from a hold rating to a buy rating and set a $7.50 price objective for the company in a research report on Tuesday, November 28th. Three investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company. The company currently has a consensus rating of Hold and an average price target of $7.50.
Shares of Chromadex (NASDAQ:CDXC) opened at $5.07 on Friday. The company has a current ratio of 5.03, a quick ratio of 4.12 and a debt-to-equity ratio of 0.01. Chromadex has a 1 year low of $2.26 and a 1 year high of $7.24.
In other Chromadex news, CEO Frank L. Jaksch, Jr. sold 28,379 shares of the stock in a transaction dated Thursday, January 11th. The stock was sold at an average price of $6.52, for a total transaction of $185,031.08. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Frank L. Jaksch, Jr. sold 58,400 shares of the stock in a transaction dated Thursday, December 21st. The stock was sold at an average price of $6.19, for a total value of $361,496.00. The disclosure for this sale can be found here. 11.59% of the stock is currently owned by corporate insiders.
A number of hedge funds have recently added to or reduced their stakes in CDXC. Goldman Sachs Group Inc. increased its holdings in Chromadex by 870.6% during the 2nd quarter. Goldman Sachs Group Inc. now owns 182,633 shares of the company’s stock worth $698,000 after purchasing an additional 163,817 shares in the last quarter. Thompson Davis & CO. Inc. bought a new position in Chromadex during the 3rd quarter worth about $128,000. Granite Investment Partners LLC increased its holdings in Chromadex by 5.7% during the 3rd quarter. Granite Investment Partners LLC now owns 250,276 shares of the company’s stock worth $1,076,000 after purchasing an additional 13,599 shares in the last quarter. Oppenheimer & Co. Inc. bought a new position in Chromadex during the 4th quarter worth about $250,000. Finally, Cetera Advisor Networks LLC bought a new position in Chromadex during the 4th quarter worth about $147,000. Hedge funds and other institutional investors own 5.80% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “Chromadex (CDXC) Given a $8.00 Price Target at HC Wainwright” was posted by Watch List News and is the property of of Watch List News. If you are reading this news story on another website, it was copied illegally and republished in violation of U.S. and international trademark & copyright legislation. The legal version of this news story can be read at https://www.watchlistnews.com/chromadex-cdxc-given-a-8-00-price-target-at-hc-wainwright/1860778.html.
Chromadex Corporation and its subsidiaries ChromaDex, Inc, ChromaDex Analytics, Inc and Spherix Consulting, Inc provide research and quality-control products and services to the natural products industry. The Company allows its business units to discover, acquire, develop and commercialize ingredient technologies that address the dietary supplement, food, beverage, skin care and pharmaceutical markets.
Receive News & Ratings for Chromadex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chromadex and related companies with MarketBeat.com's FREE daily email newsletter.